Previous close | 77.65 |
Open | 77.29 |
Bid | 78.20 x 800 |
Ask | 78.21 x 1100 |
Day's range | 77.16 - 78.29 |
52-week range | 72.87 - 89.74 |
Volume | |
Avg. volume | 5,738,222 |
Market cap | 97.384B |
Beta (5Y monthly) | 0.31 |
PE ratio (TTM) | 16.74 |
EPS (TTM) | 4.67 |
Earnings date | 31 Jan 2024 - 05 Feb 2024 |
Forward dividend & yield | 3.00 (3.86%) |
Ex-dividend date | 14 Dec 2023 |
1y target est | 89.76 |
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.